According to these guidelines, every effort should be made to increase the dose of ACE inhibitors to the target doses shown in clinical trials to decrease mortality and morbidity with close monitoring when managing chronic HF [3, 6–8]. The gene discussed is ACE; the disease is hydrops fetalis.